E-602

N/A

Report date: 2025/10/29 17:47:32
First In Class

Base Information

Drug NameE-602
Drug Alias NameBi-Sialidase人唾液酸酶融合蛋白E-602HLX-79HLX79
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionGlyco-immune checkpoint inhibitor
TargetsUpdating
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsLupus NephritisGlomerulonephritis, Membranous +[17
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPalleon Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsLupus NephritisGlomerulonephritis, Membranous +[17
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A